НЬЮМАН Роберт А. (US),ЯНГ Пейинг (US),ЭДДИНГТОН О. Крэнделл (US)
申请号：
RU2013151251/15
公开号：
RU2013151251A
申请日:
2013.11.18
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A kit for use in an in vitro prognostic "method for determining or predicting in vivo the therapeutic response of a disease or disorder having an etiology associated with excessive cell proliferation to treatment with a cardiac glycoside or a composition containing cardiac glycoside, where the kit includes: a) a first a "primary" antibody with binding affinity for the α3 isoform of the Na subunit, K-ATPase； and b) a second "primary" antibody with binding affinity for the isoform of the α3 subunit of Na, K-ATPase, c) instructions for use the selection and implementation of a prognostic analysis to predict the in vivo therapeutic response of a disease or disorder having an etiology associated with excessive cell proliferation to treatment with a cardiac glycoside or a composition containing cardiac glycoside； and d) detailed information on how to interpret the prognostic data obtained from conducting the specified prognostic method 2. The kit according to claim 1, where the kit further includes: a) a composition for lysis； b) a sample used as a positive control and containing the α3 isoform of the subunit of Na, K-ATPase； c) a sample used as a positive control and containing the isoform of the α3 subunit of Na, K-ATPase and the isoform of the α1 subunit of Na, K-ATPase； d) a sample used as a negative control and containing the isoform of the α1 subunit of Na, K-ATPase and excluding the isoform of the α3 subunit of Na, K-ATPase； e) a “second” antibody, that is, a PCH-conjugated goat anti-mouse IgG antibody (which can be used, for example, to visualize proteins of interest)； f) gel sampler1. Набор для применения в in vitro прогностическом" способе для определения или предсказания in vivo терапевтического ответа заболевания или расстройства, имеющего этиологию, связанную с избыточной пролиферацией клеток, на лечение сердечным гликозидом или композицией, содержащей сердечный гликозид, где набор включает:a) первое "первичное" антитело, обладающее аффинностью связывания
